Engineering precision nanoparticles for drug delivery.
Engineering precision nanoparticles for drug delivery.
复制标题
工程精准纳米粒子用于药物递送。
DOI：
10.1038/s41573-020-0090-8
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Langer R
中科院分区：
文献类型：
--
作者：
Mitchell MJ;Billingsley MM;Haley RM;Wechsler ME;Peppas NA;Langer R
近年来，纳米颗粒的发展已扩展到广泛的临床应用领域。纳米粒子的发展已经克服了自由疗法的局限性，并跨越了系统的、微环境的和细胞的生物屏障，这些生物屏障在不同的患者群体和疾病中是异质的。克服这种患者异质性也已通过精确治疗完成，其中个性化干预提高了治疗效果。然而，纳米颗粒的发展仍然集中在优化输送平台上，以一种通用的解决方案。随着基于脂质、聚合物和无机纳米颗粒以越来越特定的方式设计，它们可以开始以更个性化的方式优化药物输送，进入精准医疗时代。在这篇综述中，我们讨论了先进的纳米颗粒设计在非个性化和精密应用中的应用，可以用于改善精密治疗。我们专注于纳米颗粒设计的进步，克服了输送的异质性障碍，认为智能纳米颗粒设计可以提高一般输送应用的效率，同时为精确应用提供量身定制的设计，从而最终改善患者的整体结果。纳米颗粒设计的进步可以为个性化和非个性化医疗做出重大贡献。在这篇综述中，Langer, Mitchell， Peppas及其同事讨论了纳米颗粒设计的进展，克服了输送的异质性障碍，以及将这些设计改进转化为个性化医疗方法的挑战。
In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall. Advances in nanoparticle design could make substantial contributions to personalized and non-personalized medicine. In this Review, Langer, Mitchell, Peppas and colleagues discuss advances in nanoparticle design that overcome heterogeneous barriers to delivery, as well as the challenges in translating these design improvements into personalized medicine approaches.
登录
查看更多内容
影响因子：
46.2
作者：
Behzadi S;Serpooshan V;Tao W;Hamaly MA;Alkawareek MY;Dreaden EC;Brown D;Alkilany AM;Farokhzad OC;Mahmoudi M
通讯作者：
Mahmoudi M
影响因子：
4.5
作者：
Caldorera-Moore, Mary;Ramirez, Julia E. Vela;Peppas, Nicholas A.
通讯作者：
Peppas, Nicholas A.
影响因子：
9.7
作者：
Brown, Shannon B.;Wang, Lei;Sharma, Blanka
通讯作者：
Sharma, Blanka
DOI：
10.3390/antibiotics7020046
发表时间：
2018-06-09
期刊：
Antibiotics (Basel, Switzerland)
影响因子：
--
作者：
Arias LS;Pessan JP;Vieira APM;Lima TMT;Delbem ACB;Monteiro DR
通讯作者：
Monteiro DR
DOI：
10.1016/j.jconrel.2016.07.051
发表时间：
2016-09-28
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
--
作者：
Banerjee A;Qi J;Gogoi R;Wong J;Mitragotri S
通讯作者：
Mitragotri S